Cytotoxic and antitumor properties of methionine γ-lyase conjugate in combination with S-alk(en)yl–L-cysteine sulfoxides
- Authors: Abo Qoura L.1, Morozova E.A.2, Koval V.S.2, Kulikova V.V.2, Spirina T.S.3, Demidova E.A.3, Demidkina T.V.2, Pokrovsky V.S.1,3,4
-
Affiliations:
- Research Institute of Molecular and Cellular Medicine, RUDN University
- V.A. Engelgardt Institute of Molecular Biology of the Russian Academy of Sciences
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Scientific Center for Translational Medicine, Sirius University of Science and Technology
- Issue: Vol 21, No 4 (2022)
- Pages: 62-70
- Section: ORIGINAL REPORTS
- Published: 10.12.2022
- URL: https://bioterapevt.abvpress.ru/jour/article/view/1358
- DOI: https://doi.org/10.17650/1726-9784-2022-21-4-62-70
- ID: 1358
Cite item
Full Text
Abstract
Background. Enzyme prodrug therapy is a promising strategy to treat solid malignancies. The utilization of two-component systems, including an enzyme and a non-toxic prodrug, to generate cytotoxic compounds directly at the surface of the tumor cell can be successful strategy in reducing the overall toxic load on the body.
Aim. To determine antitumor activity of the pharmacological pair C115H methionine γ-lyase (C115H MGL) conjugated with daidzein (C115H MGL-Dz) and of S-alk(en)yl-L-cysteine sulfoxides against various types of solid tumors in vitro and in vivo.
Materials. MTT-test was used to determine the cytotoxicity of C115H MGL-Dz in the presence of S-alk(en)yl-L-cysteine sulfoxides in vitro against Sw620 (colon cancer), Panc1 (pancreatic cancer), and 22Rv1 (prostate cancer). Apopto- sis induction and cell cycle alteration in 22Rv1, Sw620, and SKBR3 cell lines were studied using the Muse® Caspase-3/7 and Muse® Cell Cycle Assay kits. In vivo anticancer activity was studied on Sw620, Panc1, and 22Rv1 subcutaneous xenografts in Balb/c nude mice.
Results. The C115H MGL-Dz had the maximum cytotoxic activity in the presence of S-propyl-L-cysteine sulfoxide (propiin) with IC50 values: 3.88 and 5.4 for Panc1 and 22Rv1, respectively. Dipropyl thiosulfinate formed by the β-eli-mination of propiin catalyzed by C115H MGL-Dz, induces apoptosis through both the activation of caspases and alternative pathways, and also it inhibits cell division, contributing to a decrease in the concentration of cells in the G2/M phase. The anticancer efficacy of the pharmacological pair C115H-Dz/propiin in vivo indicated a significant decrease in Panc1 tumor volume (tumor growth inhibition (TGI) 67.5 %, p = 0.004), Sw620 (TGI 22.07 %, p = 0.12) and 22Rv1 (TGI 70 %, p = 0.043).
Conclusion. Pharmacological pair C115H MGL-Dz/propiin was capable of suppressing tumor development in malignant solid tumors and might be considered as a potential anticancer approach in cancer prodrug therapy.
About the authors
L. Abo Qoura
Research Institute of Molecular and Cellular Medicine, RUDN University
ORCID iD: 0000-0001-5391-5077
6 Miklukho-Maklaya St., 117198 Moscow
Russian FederationE. A. Morozova
V.A. Engelgardt Institute of Molecular Biology of the Russian Academy of Sciences
ORCID iD: 0000-0003-2922-2793
32 Vavilova St., 119991 Moscow
Russian FederationV. S. Koval
V.A. Engelgardt Institute of Molecular Biology of the Russian Academy of Sciences
32 Vavilova St., 119991 Moscow
Russian FederationV. V. Kulikova
V.A. Engelgardt Institute of Molecular Biology of the Russian Academy of Sciences
ORCID iD: 0000-0003-0618-1407
32 Vavilova St., 119991 Moscow
Russian FederationT. S. Spirina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
24 Kashirskoe Shosse, 115522 Moscow
Russian FederationE. A. Demidova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
24 Kashirskoe Shosse, 115522 Moscow
Russian FederationT. V. Demidkina
V.A. Engelgardt Institute of Molecular Biology of the Russian Academy of Sciences
32 Vavilova St., 119991 Moscow
Russian FederationV. S. Pokrovsky
Research Institute of Molecular and Cellular Medicine, RUDN University; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Scientific Center for Translational Medicine, Sirius University of Science and Technology
Author for correspondence.
Email: v.pokrovsky@ronc.ru
ORCID iD: 0000-0003-4006-9320
Vadim Sergeevich Pokrovsky
6 Miklukho-Maklaya St., 117198 Moscow
24 Kashirskoe Shosse, 115522 Moscow
1 Olympiyskiy Ave., 354340 Sochi
Russian FederationReferences
Supplementary files

